Adagene (ADAG) Payables (2019 - 2026)
Adagene (ADAG) posted quarterly Payables of $7152.7 billion for Q4 2025, down 21.49% year-over-year from $9110.7 billion in Q4 2024, and up 125011343.47% quarter-over-quarter from $5.7 million in Q2 2025.
Adagene (ADAG) Payables (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Payables for 7 consecutive years, with $7152.7 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Payables fell 21.49% year-over-year to $7152.7 billion; the TTM figure through Dec 2025 stood at $7152.7 billion (down 21.49% YoY), while the FY2025 annual figure was $7152.7 billion, down 21.49% from the prior year.
- Payables advanced to $7152.7 billion in Q4 2025 per ADAG's latest filing, from $5.7 million in the prior quarter.
- Across five years, Payables topped out at $14434.9 billion in Q4 2022 and bottomed at $5.7 million in Q2 2025.
- Historically, Payables has averaged $6213.3 billion across 5 years, with a median of $7241.0 billion in 2023.
- Annual changes were most pronounced in 2022 — Payables soared 224044991.29% — and 2024, when it plunged 100.0%.
- Adagene's Payables stood at $6.4 million in 2021, then jumped by 224044991.29% to $14434.9 billion in 2022, then tumbled by 49.22% to $7329.4 billion in 2023, then rose by 24.3% to $9110.7 billion in 2024, then decreased by 21.49% to $7152.7 billion in 2025.
- Business Quant data shows ADAG's Payables at $7152.7 billion in Q4 2025, $5.7 million in Q2 2025, and $9110.7 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - | 19.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.94 Mn |
| Dec 31, 2025 | 7,152.66 Bn |
| Jun 30, 2025 | 5.72 Mn |
| Dec 31, 2024 | 9,110.73 Bn |
| Jun 30, 2024 | 7.58 Mn |
| Dec 31, 2023 | 7,329.43 Bn |
| Jun 30, 2023 | 13,479.32 Bn |
| Dec 31, 2022 | 14,434.87 Bn |
| Jun 30, 2022 | 10,625.88 Bn |
| Dec 31, 2021 | 6.44 Mn |
| Jun 30, 2021 | 6.69 Mn |
| Dec 31, 2020 | 5.64 Mn |
| Dec 31, 2019 | 1.43 Mn |